News
Merck is going all-in on domestic drug manufacturing with a $1 billion Delaware facility aimed at dodging Trump-era tariff ...
This article is authored by Aditya Sharma, head, Process Solutions, India Region, Merck Life Science, New Delhi.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback